Mark Denison Archives
Nov. 17, 2022—Nine current faculty members of the Vanderbilt University School of Medicine have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
Nov. 3, 2022—The public is invited to listen in as scientists on the forefront of COVID-19 research at Vanderbilt University Medical Center share their personal stories on Wednesday afternoon, Nov. 16, in 214 Light Hall.
Dolly Parton donates $1 million to pediatric infectious disease research at Vanderbilt University Medical Center
Jun. 15, 2022—Dolly Parton is donating $1 million to pediatric infectious disease research at Vanderbilt University Medical Center to help in the fight against serious infectious diseases such as coronavirus that have worldwide ramifications.
May. 5, 2022—The 2022 Vanderbilt University School of Medicine Academic Enterprise Awards for Excellence in Teaching, Extraordinary Performance of Clinical Service, and Outstanding Contributions to Research were presented April 29 during the annual spring faculty meeting.
Apr. 21, 2022—Physician-scientists from Vanderbilt University Medical Center were well represented at the recent annual meeting of the American Society for Clinical Investigation (ASCI), Association of American Physicians (AAP) and the American Physician-Scientist Association.
Nov. 23, 2021—Researchers at Vanderbilt University Medical Center who contributed to the development of Moderna’s COVID-19 vaccine are featured in a new exhibit at the Smithsonian Institution in Washington, D.C.
Nov. 18, 2021—Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
Oct. 1, 2021—Vanderbilt research helped allow pharmaceutical giant Merck & Co. to authorization for the first oral antiviral pill to treat COVID-19.
Oct. 26, 2020—Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.
Jul. 14, 2020—An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.
Jul. 9, 2020—This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.